RxDoctor Payments Data

Justin Burks

Family · Springfield, MONPI 1518596089

Payments from drug & device makers

$1,087in general payments, 2019–2025

Across 49 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$268
  • Actelion Pharmaceuticals US, Inc.$227
  • GSK$110
  • Boehringer Ingelheim$87
  • Takeda Pharmaceuticals U.S.A., Inc.$74
  • Merck$70
  • plus $249 from 9 others

What the payments were for

  • Food & beverage$98891%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,087 in reported general payments places this provider in the 65th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$29,256
Medicare patients
228
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag16$333,240
OfevNintedanib Esylate25$317,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter380$298,026
Breztri AerosphereBudesonide/Glycopyr/Formoterol190$161,369
Orenitram ErTreprostinil Diolamine11$104,151
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr172$83,792
Spiriva RespimatTiotropium Bromide120$79,862
Stiolto RespimatTiotropium Br/Olodaterol Hcl83$51,139
Spiriva HandihalerTiotropium Bromide71$40,725
Breo ElliptaFluticasone/Vilanterol81$35,863
SymbicortBudesonide/Formoterol Fumarate120$32,238
Incruse ElliptaUmeclidinium Bromide81$31,942
Advair HfaFluticasone Propion/Salmeterol34$13,006
Fluticasone-SalmeterolFluticasone Propion/Salmeterol91$11,049
Sildenafil Citrate29$9,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$110$449,624714 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$87$448,363228 claims
Actelion Pharmaceuticals US, Inc.Uptravi$227$333,24016 claims
AstraZenecaBreztri Aerosphere, Symbicort$268$193,607310 claims
MerckDulera$70$6,66020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,812 family providers in Missouri.

Other family in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →